Genective Revenue and Competitors
Estimated Revenue & Valuation
- Genective's estimated annual revenue is currently $6.7M per year.
- Genective's estimated revenue per employee is $155,000
Employee Data
- Genective has 43 Employees.
- Genective grew their employee count by -2% last year.
Genective's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Finance, CFO | Reveal Email/Phone |
2 | Head Entomology | Reveal Email/Phone |
3 | Head Research Entomology | Reveal Email/Phone |
4 | Head Quality Management and Compliance | Reveal Email/Phone |
5 | Head In Vitro Entomology | Reveal Email/Phone |
6 | Head Bioinformatics | Reveal Email/Phone |
7 | Head Research Entomology | Reveal Email/Phone |
8 | VP Research | Reveal Email/Phone |
9 | Head Quality Management & Compliance | Reveal Email/Phone |
10 | Project Manager | Reveal Email/Phone |
Genective Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Genective?
Genective is a 50/50 joint venture between Limagrain and KWS, two of the world's largest seed companies. With entities and activities in North America, South America, Europe, and Asia, Genective is currently dedicated to the research, development, and commercialization of transgenic traits.
keywords:N/AN/A
Total Funding
43
Number of Employees
$6.7M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.7M | 43 | 0% | N/A |
#2 | $35M | 44 | 19% | N/A |
#3 | $3.5M | 44 | 2% | N/A |
#4 | $7.2M | 44 | 10% | N/A |
#5 | $5.3M | 44 | 83% | N/A |